TheraRadar
Landscape → Oncology

Gastric Cancer Clinical Trial Landscape

Data updated: May 20, 2026

1,057 clinical trials tracked since 2008

Gastric cancer, also known as stomach cancer, occurs when cells in the stomach grow out of control. It can affect anyone, but is more common in older adults and certain populations. The clinical trial landscape for gastric cancer is active, with 1,055 trials registered since 2008, and 493 currently active. Activity is heavily concentrated in early-phase trials, with 178 active Phase 1 and 316 active Phase 2 trials, compared to 84 active Phase 3 and 13 active Phase 4 trials. AstraZeneca leads industry sponsorship of active trials with 13, followed by Astellas Pharma Global Development, Inc. with 5, Chongqing Precision Biotech Co., Ltd with 5, Sichuan Baili Pharmaceutical Co., Ltd. with 4, and Roche with 3. The high proportion of Phase 1 and 2 trials suggests a strong focus on novel therapeutic approaches and early-stage drug development in gastric cancer.

492 active
/
1057 total (since 2008)
179
Phase 1 Active
403 total
313
Phase 2 Active
642 total
85
Phase 3 Active
182 total
12
Phase 4 Active
33 total

Top Industry Sponsors

Sorted by active Active Done Failed
AstraZeneca 13 3 2
Astellas Pharma Global Development, Inc. 5 2 0
Chongqing Precision Biotech Co., Ltd 5 0 0
Sichuan Baili Pharmaceutical Co., Ltd. 4 0 0
Roche 3 9 5

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT04704934 ACTIVE NOT RECRUITING
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Daiichi Sankyo n=490
NCT06203600 RECRUITING
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
National Cancer Institute (NCI) n=224
NCT06764875 RECRUITING
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
AstraZeneca n=840
NCT07043400 RECRUITING
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
BeOne Medicines n=351
NCT05677490 RECRUITING
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Alliance for Clinical Trials in Oncology n=382

+ 177 more Phase 3 trials — see full database below

Gastric Cancer — Trials Started by Year (last 10 years)

2016
38
2017
46
2018
53
2019
50
2020
67
2021
77
2022
76
2023
79
2024
116
2025
108
2026
57

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

AstraZeneca
18
Astellas Pharma Global Development, Inc.
7
Chongqing Precision Biotech Co., Ltd
5
Sichuan Baili Pharmaceutical Co., Ltd.
4
Roche
17
Amgen
7
Jiangsu HengRui Medicine Co., Ltd.
7
Seagen, a wholly owned subsidiary of Pfizer
4
RemeGen Co., Ltd.
4
Daiichi Sankyo
3

Active Trials by Phase

Phase 1
179
Phase 2
313
Phase 3
85
Phase 4
12

Enrollment Size Distribution

1-50
454
51-200
352
201-500
127
501-1k
79
1k+
12

All Industry Sponsors

Sorted by active Active Done Failed
AstraZeneca 13 3 2
Astellas Pharma Global Development, Inc. 5 2 0
Chongqing Precision Biotech Co., Ltd 5 0 0
Sichuan Baili Pharmaceutical Co., Ltd. 4 0 0
Roche 3 9 5
Amgen 3 2 2
Jiangsu HengRui Medicine Co., Ltd. 3 4 0
Seagen, a wholly owned subsidiary of Pfizer 3 1 0
RemeGen Co., Ltd. 3 1 0
Daiichi Sankyo 3 0 0
BeOne Medicines 3 0 0
SystImmune Inc. 3 0 0
Qilu Pharmaceutical Co., Ltd. 3 0 0
Shanghai JMT-Bio Inc. 3 0 0
Ono Pharmaceutical Co., Ltd. 2 3 0
NCT07584135 NOT YET RECRUITING
JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
NingBo Junyan Hongshi Biosciences Co., Ltd n=600
NCT04704934 ACTIVE NOT RECRUITING
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Daiichi Sankyo n=490
NCT06203600 RECRUITING
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
National Cancer Institute (NCI) n=224
NCT06764875 RECRUITING
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
AstraZeneca n=840
NCT07043400 RECRUITING
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
BeOne Medicines n=351
NCT05677490 RECRUITING
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Alliance for Clinical Trials in Oncology n=382
NCT07000253 RECRUITING
Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=290
NCT04248452 ACTIVE NOT RECRUITING
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
ECOG-ACRIN Cancer Research Group n=314
NCT07001748 RECRUITING
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
ECOG-ACRIN Cancer Research Group n=148
NCT03504397 ACTIVE NOT RECRUITING
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
Astellas Pharma Global Development, Inc. n=565
NCT06901531 RECRUITING
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Astellas Pharma Global Development, Inc. n=500
NCT06346197 RECRUITING
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
Centre Leon Berard n=132
NCT07217704 RECRUITING
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
SOFIE n=200
NCT03653507 ACTIVE NOT RECRUITING
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
Astellas Pharma Global Development, Inc. n=507
NCT07431281 RECRUITING
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca n=2,130
NCT07392892 RECRUITING
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Pfizer n=840
NCT07518147 NOT YET RECRUITING
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
Sichuan Baili Pharmaceutical Co., Ltd. n=438
NCT06731478 RECRUITING
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Daiichi Sankyo n=726
NCT06346392 RECRUITING
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca n=572
NCT05871099 RECRUITING
Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not
The Affiliated Hospital of Qingdao University n=616
NCT06532006 RECRUITING
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Shanghai Henlius Biotech n=550
NCT05052801 ACTIVE NOT RECRUITING
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Amgen n=547
NCT04871412 RECRUITING
The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III
Ottawa Hospital Research Institute n=20
NCT03399110 ACTIVE NOT RECRUITING
XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)
Fudan University n=1,024
NCT06206733 ACTIVE NOT RECRUITING
ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma
AskGene Pharma, Inc. n=780
NCT07366528 RECRUITING
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Ruijin Hospital n=387
NCT04342910 RECRUITING
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Jiangsu HengRui Medicine Co., Ltd. n=550
NCT07331454 NOT YET RECRUITING
Robotic vs Laparoscopic Gastrectomy for cT4a Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University n=335
NCT07332533 NOT YET RECRUITING
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
Shanghai JMT-Bio Inc. n=490
NCT07314203 NOT YET RECRUITING
Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer
Fujian Medical University n=118
NCT07304271 RECRUITING
Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastasis
Magnus Nilsson n=262
NCT07029269 RECRUITING
Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
Zuoyi Jiao n=454
NCT06093425 NOT YET RECRUITING
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Suzhou Transcenta Therapeutics Co., Ltd. n=820
NCT05111626 ACTIVE NOT RECRUITING
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
Amgen n=515
NCT06988475 RECRUITING
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
Cancer Research UK n=30
NCT07241715 ACTIVE NOT RECRUITING
Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE)
National University Hospital, Singapore n=300
NCT07152405 RECRUITING
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd. n=490
NCT07103668 RECRUITING
A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients
Suzhou Immunofoco Biotechnology Co., Ltd n=150
NCT05980481 ACTIVE NOT RECRUITING
A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
RemeGen Co., Ltd. n=201
NCT06826079 RECRUITING
Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology n=80
NCT07018661 RECRUITING
[18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer
Leiden University Medical Center n=250
NCT05002127 ACTIVE NOT RECRUITING
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
ALX Oncology Inc. n=127
NCT06793917 RECRUITING
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Fujian Cancer Hospital n=269
NCT07068516 NOT YET RECRUITING
Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer
Xiangdong Cheng n=470
NCT06949033 RECRUITING
Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Zuoyi Jiao n=668
NCT06939439 ACTIVE NOT RECRUITING
Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University n=416
NCT06232434 RECRUITING
An Open Prospective Randomized Clinical Study of the Effectiveness, Tolerability and Safety of a Single Intraperitoneal Use of the Drug "Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1" in Patients With Disseminated Gastric Cancer, Phase I-II
Research Institute for Physical Chemical Problems of the Belarusian State University n=120
NCT05482516 RECRUITING
Evaluating Novel Therapies in ctDNA Positive GI Cancers
Georgetown University n=20
NCT06028737 RECRUITING
Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
Ukrainian Society of Clinical Oncology n=150
NCT06925243 RECRUITING
Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Zuoyi Jiao n=682
NCT06755554 RECRUITING
Investigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer
Ukrainian Society of Clinical Oncology n=105
NCT01924819 ACTIVE NOT RECRUITING
Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
Australasian Gastro-Intestinal Trials Group n=574
NCT05303714 RECRUITING
PIPAC in Multimodal Therapy for Patients with Oligometastatic Peritoneal Gastric Cancer
Azienda Ospedaliera Universitaria Integrata Verona n=98
NCT06782412 RECRUITING
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
KU Leuven n=109
NCT04214990 RECRUITING
Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients
National Cancer Center, Korea n=1,700
NCT02112214 ACTIVE NOT RECRUITING
Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population
National Cancer Center, Korea n=5,224
NCT06296706 RECRUITING
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=630
NCT04447352 RECRUITING
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
Krankenhaus Nordwest n=200
NCT06608381 RECRUITING
Comparison Partial Versus Total Omentectomy in Minimal Invasive Distal Gastrectomy for cT3/4a Gastric Cancer (KLASS-10)
Gangnam Severance Hospital n=440
NCT05144854 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Ono Pharmaceutical Co., Ltd. n=626
NCT06313567 RECRUITING
Metronomic Capecitabine in Stage III Gastric Cancer
Fudan University n=722
NCT06161207 RECRUITING
3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer
Fujian Medical University n=702
NCT01882933 ACTIVE NOT RECRUITING
D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma
Hospices Civils de Lyon n=367
NCT06221748 RECRUITING
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
RemeGen Co., Ltd. n=90
NCT04597294 RECRUITING
Prophylactic Preoperative HIPEC in Advanced Gastric Cancer at High Risk of Peritoneal Recurrence
Jagiellonian University n=600
NCT06177041 RECRUITING
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
FutureGen Biopharmaceutical (Beijing) Co., Ltd n=486
NCT01917552 RECRUITING
Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS
Asan Medical Center n=870
NCT01935778 RECRUITING
Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH
Asan Medical Center n=286
NCT05918094 RECRUITING
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
Sun Yat-sen University n=540
NCT06123494 RECRUITING
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
Jiangsu HengRui Medicine Co., Ltd. n=360
NCT05427383 RECRUITING
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Shanghai JMT-Bio Inc. n=286
NCT06115629 NOT YET RECRUITING
Surveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial
University of Dublin, Trinity College n=952
NCT04611997 ACTIVE NOT RECRUITING
IGG Using in Laparoscopic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
Fujian Medical University n=240
NCT05914610 NOT YET RECRUITING
Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer
Fujian Medical University n=100
NCT05813015 RECRUITING
Study of Comparing of With and Without Sequential Therapy of S-1
Zhejiang University n=70
NCT05300945 NOT YET RECRUITING
HIPEC Combined Gastrectomy in Patients With Advanced Gastric Cancer Received Neoadjuvant Chemotherapy
Zhixin Cao n=200
NCT05610332 NOT YET RECRUITING
Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
Fujian Medical University n=216
NCT05230771 NOT YET RECRUITING
Clinical Outcome of Palliative Surgery After Translational Therapy for Metastatic Gastric Cancer Versus Maintenance Chemotherapy for Metastatic Gastric Cancer
Fujian Medical University n=120
NCT04787354 RECRUITING
Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)
Hallym University Medical Center n=976
NCT04997837 RECRUITING
Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
Fudan University n=433
NCT04384601 NOT YET RECRUITING
Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
Ruijin Hospital n=246
NCT04483076 RECRUITING
Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer
Chinese PLA General Hospital n=524
NCT04677673 NOT YET RECRUITING
Neoadjuvant Chemotherapy Plus Surgery Versus Surgery First For Elderly Gastric Cancer Patients
BIRENDRA KUMAR SAH n=232
NCT03941561 RECRUITING
S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC）
Fudan University n=1,006
NCT03961373 RECRUITING
Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer
University of Siena n=539
NCT03221426 COMPLETED
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
Merck Sharp & Dohme LLC n=1,007
NCT04882241 COMPLETED
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
Merck Sharp & Dohme LLC n=120
NCT07437573 COMPLETED
Oncometabolic Surgery
Korea University Guro Hospital n=94
NCT03042169 TERMINATED
Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer
University Hospital, Lille n=6
NCT04157985 COMPLETED
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg n=161
NCT03223376 COMPLETED
A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
Hutchison Medipharma Limited n=703
NCT05008783 COMPLETED
A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma
Akeso n=610
NCT03813784 COMPLETED
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd. n=885
NCT02872116 COMPLETED
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
Bristol-Myers Squibb n=2,031
NCT01815853 COMPLETED
Neoadjuvant Chemoradiotherapy vs. Chemotherapy Followed by Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer
Sun Yat-sen University n=620
NCT04082364 COMPLETED
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
MacroGenics n=82
NCT04032119 COMPLETED
RCT of Gastric ESD With or Without Epineprhine Added Solution
Chinese University of Hong Kong n=800
NCT02349412 COMPLETED
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology n=405
NCT04499924 COMPLETED
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
Seagen Inc. n=17
NCT02867839 TERMINATED
Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer
Peking University Cancer Hospital & Institute n=29
NCT02578368 COMPLETED
Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
Krankenhaus Nordwest n=183
NCT01285557 TERMINATED
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
Taiho Oncology, Inc. n=361
NCT02500043 COMPLETED
Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer
Taiho Oncology, Inc. n=507
NCT01839773 COMPLETED
Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer
Daehwa Pharmaceutical Co., Ltd. n=238
NCT02746796 COMPLETED
Study of ONO-4538 in Gastric Cancer
Ono Pharmaceutical Co., Ltd. n=680
NCT03006705 COMPLETED
Study of Adjuvant ONO-4538 With Resected Gastric Cancer
Ono Pharmaceutical Co., Ltd. n=800
NCT02267343 COMPLETED
Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer
Ono Pharmaceutical Co., Ltd. n=493
NCT01924533 COMPLETED
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
AstraZeneca n=525
NCT03607656 COMPLETED
The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer
Shanghai University of Traditional Chinese Medicine n=270
NCT01515748 COMPLETED
Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer
Sanofi n=530
NCT02519140 WITHDRAWN
Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections
Antonios Likourezos
NCT03802591 COMPLETED
A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma
CStone Pharmaceuticals n=479
NCT02178956 COMPLETED
A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
Sumitomo Pharma America, Inc. n=714
NCT02853474 COMPLETED
Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy
Centre Oscar Lambret n=480
NCT02494583 COMPLETED
Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
Merck Sharp & Dohme LLC n=763
NCT04675983 TERMINATED
A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)
Innovent Biologics (Suzhou) Co. Ltd. n=36
NCT03745170 COMPLETED
Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer
Innovent Biologics (Suzhou) Co. Ltd. n=650
NCT02661971 COMPLETED
FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest n=180
NCT03042611 COMPLETED
A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer
Elevar Therapeutics n=460
NCT02898077 COMPLETED
A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
Eli Lilly and Company n=440
NCT02370498 COMPLETED
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)
Merck Sharp & Dohme LLC n=592
NCT03130790 COMPLETED
Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)
ASLAN Pharmaceuticals n=52
NCT02322593 COMPLETED
Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer
Taiho Pharmaceutical Co., Ltd. n=711
NCT02395640 COMPLETED
The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer
Fudan University n=438
NCT02314117 COMPLETED
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
Eli Lilly and Company n=645
NCT03196791 COMPLETED
Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient
Korea University Anam Hospital n=196
NCT01774786 COMPLETED
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
Hoffmann-La Roche n=780
NCT02625623 COMPLETED
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
EMD Serono Research & Development Institute, Inc. n=371
NCT02114359 COMPLETED
Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer
Seoul National University Hospital n=111
NCT02581462 COMPLETED
FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest n=81
NCT02545504 COMPLETED
Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Gilead Sciences n=432
NCT02557932 COMPLETED
Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication
National Cancer Center, Korea n=352
NCT01516944 COMPLETED
Perioperative Chemotherapy for Potentially Resectable Gastric Cancer
Hebei Medical University n=749
NCT01248403 COMPLETED
A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy
Krankenhaus Nordwest n=300
NCT00915382 COMPLETED
Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer: SOS
Asan Medical Center n=625
NCT01470742 WITHDRAWN
Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer
Samsung Medical Center
NCT00941655 COMPLETED
Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
National Cancer Institute (NCI) n=15
NCT02076594 TERMINATED
Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente n=171
NCT00917384 COMPLETED
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
Eli Lilly and Company n=355
NCT01170663 COMPLETED
A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma
Eli Lilly and Company n=665
NCT01216644 COMPLETED
5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
Krankenhaus Nordwest n=716
NCT02736552 WITHDRAWN
Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.
Fudan University
NCT02490111 COMPLETED
Clinical Trials for the Prevention of Gallstone Formation After Gastrectomy in Patient With Gastric Cancer
Daewoong Pharmaceutical Co. LTD. n=521
NCT03350477 COMPLETED
Bioinformation Therapy for Gastric Cancer
Fuda Cancer Hospital, Guangzhou n=120
NCT01824459 COMPLETED
S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients
Sun Yat-sen University n=576
NCT02120885 COMPLETED
An Effect of an Individualized Physical Activity Intervention for Gastric Cancer Patient Undergoing Minimally Invasive Gastrectomy: a Phase III, Prospective Randomized Controlled Trial
Yonsei University n=70
NCT01065688 COMPLETED
A Trial of Reconstruction After Distal Gastrectomy for Gastric Cancer
Wakayama Medical University n=120
NCT02706184 COMPLETED
E. Coli Nissle in Oncology
University of Hohenheim n=20
NCT02150447 TERMINATED
The Use of Proton Pump Inhibitor on the Prevention of Gastric Cancer Bleeding
National Cancer Center, Korea n=394
NCT01813253 TERMINATED
Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer
Kuhnil Pharmaceutical Co., Ltd. n=400
NCT01683864 TERMINATED
Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer
University Hospital Tuebingen n=3
NCT01641939 TERMINATED
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
Hoffmann-La Roche n=415
NCT00887822 COMPLETED
A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer
Hoffmann-La Roche n=202
NCT01646476 COMPLETED
Covered Versus Uncovered Self-expandable Metallic Stents for Malignant Gastric Outlet Obstruction
Samsung Medical Center n=102
NCT03067792 COMPLETED
FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer
Yonsei University n=52
NCT01099085 COMPLETED
Trial of XP (Capecitabine/CDDP) Simvastatin in Advanced Gastric Cancer Patients
Samsung Medical Center n=207
NCT01433861 TERMINATED
Laparoscopy-assisted Proximal Gastrectomy Versus and Laparoscopy-assisted Total Gastrectomy
Seoul National University Bundang Hospital n=7
NCT02988635 COMPLETED
Early Palliative Care on Quality of Life of Advanced Cancer Patients
Azienda Ospedaliero-Universitaria di Parma n=281
NCT01450696 TERMINATED
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Hoffmann-La Roche n=296
NCT01662869 COMPLETED
A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer
Hoffmann-La Roche n=564
NCT01512745 COMPLETED
Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd. n=267
NCT02137343 TERMINATED
A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer
Amgen n=34
NCT01697072 TERMINATED
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Amgen n=609
NCT01671449 COMPLETED
S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer
Min-Hee Ryu n=338
NCT00879333 COMPLETED
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
Novartis Pharmaceuticals n=656
NCT02168426 COMPLETED
Randomized Control Trial on Seprafilm and Guardix in Preventing Ileus
Gachon University Gil Medical Center n=200
NCT02219529 COMPLETED
Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases
Changhai Hospital n=350
NCT02444897 COMPLETED
The Comparison Between Epidural and Intravenous Patient-controlled Analgesia for Laparoscopic Gastrectomy
Keimyung University Dongsan Medical Center n=60
NCT02445209 COMPLETED
Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma
Jagiellonian University n=56
NCT02442362 COMPLETED
TOF Versus SOX in Metastatic Gastric Cancer
The First People's Hospital of Changzhou n=60
NCT00718354 COMPLETED
Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT
Thrombosis Research Institute n=740
NCT01989858 TERMINATED
ITACA-S2 (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach)
Mario Negri Institute for Pharmacological Research n=1,180
NCT00678535 COMPLETED
Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer
Merck KGaA, Darmstadt, Germany n=904
NCT01971775 COMPLETED
Clinical Study for Energy Based Devices in Open Gastrectomy for Gastric Cancer
Seoul National University Hospital n=56
NCT01491698 COMPLETED
Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Health-Related Quality of Life in Patients Undergoing Total Gastrectomy for Adenocarcinoma
Memorial Sloan Kettering Cancer Center n=12
NCT00978549 COMPLETED
Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer
Cambridge University Hospitals NHS Foundation Trust n=320
NCT00824785 TERMINATED
REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer
Royal Marsden NHS Foundation Trust n=574
NCT01411176 COMPLETED
Phase III Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy
Nihon Pharmaceutical Co., Ltd n=85
NCT01411189 COMPLETED
Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy
Nihon Pharmaceutical Co., Ltd n=33
NCT00821990 COMPLETED
Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer
Samsung Medical Center n=200
NCT00639327 COMPLETED
Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer
Japan Clinical Cancer Research Organization n=300
NCT00606619 COMPLETED
Effects of Early Oral Feeding After Resection of Gastric Cancer
The Catholic University of Korea n=58

Full Gastric Cancer Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only